格隆汇9月10日丨海利生物(603718.SH)公布，控股子公司陕西瑞盛生物科技有限公司（简称"瑞盛生 物"）于近日收到国家药品监督管理局下发的医疗器械注册申请受理通知信息，产品名称：天然骨修复 材料。本产品骨修复材料，根据《医疗器械分类规则》（局令第15号）、《医疗器械分类目录》（2017 年第104号公告），本产品为Ⅲ类医疗器械，属于17口腔科器械，一级产品类别为"17-08口腔植入及组 织重建材料"，二级产品类别为"17-08-06骨填充及修复材料"，产品分类编码为17-08-06。该产品获批上 市后可在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

海利生物公告，控股子公司陕西瑞盛生物科技有限公司于近日收到国家药品监督管理局下发的医疗器械 注册申请受理通知。该医疗器械为天然骨修复材料，适用于颌骨缺损修复。受理号为CQZ2501670，产 品类别为第三类医疗器械。目前注册申请已获得受理，后续需经过审评审批、制证等流程。该产品为Ⅲ 类医疗器械，获批上市后将在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.2% on September 4, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (code: 838275) with a closing price of 11.96, up 6.50% [1] - Dayu Biological (code: 871970) with a closing price of 10.04, up 3.40% [1] - Yongshun Biological (code: 839729) with a closing price of 10.39, up 2.26% [1] - Conversely, Shunlian Biological (code: 688098) saw a decline of 2.98%, closing at 11.40 [2] Trading Volume and Capital Flow - The total trading volume for the animal health sector showed a net outflow of 85.41 million yuan from institutional investors, while retail investors saw a net inflow of 74.17 million yuan [2] - The capital flow for individual stocks indicated significant movements, with Shunlian Biological experiencing a net outflow of 10.12 million yuan from institutional investors [3] Individual Stock Analysis - Shunlian Biological had a total trading volume of 131,200 shares, with a net inflow of 7.73 million yuan from retail investors [3] - Other stocks like Huisheng Biological (code: 300871) and ST Green Kang (code: 002868) also showed varied capital flows, with Huisheng experiencing a net outflow of 12.50 million yuan from speculative funds [3]

Market Overview - The animal health sector experienced a decline of 2.2% on September 3, with the leading stock, Driveline, falling by 8.33% [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Key stocks in the animal health sector showed significant declines, with Driveline (code: 838275) closing at 11.23, down 8.33% on a trading volume of 49,500 shares and a transaction value of 57.66 million yuan [1] - Other notable declines included: - Yongshun Biological (code: 839729) down 4.78% to 10.16 [1] - Jinhai Biological (code: 002688) down 4.03% to 6.91 [1] - ST Lvkang (code: 002868) down 3.30% to 26.35 [1] - Houbang Holdings (code: 002141) down 3.24% to 3.88 [1] Capital Flow - The animal health sector saw a net outflow of 108 million yuan from major funds, while retail investors contributed a net inflow of 101 million yuan [1] - Detailed capital flow for specific stocks indicated: - Shunlian Biological (code: 688098) had a net inflow of 8.21 million yuan from major funds [2] - ST Lvkang (code: 002868) experienced a net outflow of 2.26 million yuan from major funds [2] - Houbang Holdings (code: 002141) faced a significant net outflow of 24.59 million yuan from major funds [2]

Core Viewpoint - Shanghai Haili Biological Technology Co., Ltd. announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the registration application of three types of medical devices, specifically "bone repair materials" [1] Group 1: Product Details - The products are classified as Class III medical devices, suitable for filling and repairing maxillofacial bone defects and alveolar bone defects (or insufficient bone volume) [1] - The application includes structured products such as block and column types, which can better match the bone defect areas compared to the existing granular bone repair materials, effectively reducing bone powder displacement and improving surgical efficiency and osteogenic effects [1] Group 2: Regulatory Process - The registration application is currently in the review and approval stage, with a statutory administrative approval period of 20 working days, which can be extended by an additional 10 working days under special circumstances [1] Group 3: Market Implications - If the product is successfully approved for market launch, it will enrich Haili Biological's product line in the field of oral bone defect repair [1] - The company notes that the product is still in the acceptance stage, and its impact on future performance remains uncertain [1]

格隆汇9月1日丨海利生物(603718.SH)公布，控股子公司陕西瑞盛生物科技有限公司（简称"瑞盛生 物"）于近日收到国家药品监督管理局下发的医疗器械注册申请受理通知信息，产品名称：骨修复材 料。本产品骨修复材料，根据《医疗器械分类规则》（局令第15号）、《医疗器械分类目录》（2017年 第104号公告），本产品为Ⅲ类医疗器械，属于17口腔科器械，一级产品类别为"17-08口腔植入及组织 重建材料"，二级产品类别为"17-08-06骨填充及修复材料"，产品分类编码为17-08-06。该产品获批上市 后可在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

证券代码：603718 证券简称：海利生物 公告编号：2025－038 上海海利生物技术股份有限公司 关于控股子公司三类医疗器械注册申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生物 科技有限公司（以下简称"瑞盛生物"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）下发的医疗器械注册申请受理通知信息，现将相关情况公告如下： 一、该医疗器械的基本信息 申请人：陕西瑞盛生物科技有限公司 产品名称：骨修复材料 临床用途：适用于颌面骨缺损、牙槽骨缺损（或骨量不足）填充和修复 该医疗器械目前注册申请已获得受理。 三、 后续所需审批流程 后续所需的审批流程：审评审批、制证。 办结时限：行政审批 20 个工作日，特殊情况延长 10 个工作日。检验检测，技术 审评等不计入法定审批时限。 四、产品相关情况 口腔科骨缺损修复手术主要针对牙槽骨缺损或吸收导致的功能与美观问题，常见 于牙周炎、外伤或种植牙术前骨量不足。手术通过植入骨修复材料（如自体 ...

Core Viewpoint - The announcement indicates that the application for the registration of bone repair materials by Shaanxi Ruisheng Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration, which is a significant step for the company in expanding its product line in the dental field [1] Group 1 - The bone repair material is designed for filling and repairing maxillofacial bone defects and alveolar bone deficiencies, making it a critical material for oral surgery [1] - The new product will supplement the existing bone repair materials offered by Ruisheng Biotechnology, thereby enriching its product portfolio [1] - Currently, the product is in the acceptance stage, and it is expected that there will be no definitive impact on the company's existing business and operating performance [1]

Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]